Sentences with phrase «urothelial carcinoma»
"Urothelial carcinoma" is a term used to describe a type of cancer that starts in the cells lining the urinary system, particularly the bladder. It is a simple way to refer to a specific form of cancer that affects these particular cells. Full definition
The main purpose of this study is to assess how metastatic or surgically unresectable urothelial carcinoma with FGF / FGFR alterations responds to treatment with the study drug, INCB054828.
vicc.org
The US Food and Drug Administration granted accelerated approval to avelumab (Bavencio) in May 2017, for the treatment of locally advanced or metastatic urothelial carcinoma patients whose disease progressed on or following platinum - containing chemotherapy.
Early oncological outcomes for bladder urothelial carcinoma patients treated with robotic - assisted radical cystectomy.
A Phase 2, Open - Label, Single - Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF / FGFR Alterations
Alterations to DDR genes were associated with improved outcomes in patients with metastatic urothelial carcinoma who were treated with immunotherapy.
Chronic bladder infection also leads to inflammation and can manifest Urothelial Carcinoma.
Breeds at risk for developing urothelial carcinoma include Scottish Terriers, West Highland White Terriers, beagles, and Shetland sheepdogs.
TCC is also called urothelial carcinoma.
Canine TCC is almost identical to human invasive TCC (invasive urothelial carcinoma) in histopathologic characteristics, molecular features studied to date, biologic behavior (sites and frequency of metastasis), and response to medical therapy.
Inclusion Criteria: • Histologically documented metastatic or surgically unresectable urothelial carcinoma; may include primary site from ureters, upper tract, renal pelvis, and bladder.
A Randomized Phase 2 Trial of Cisplatin / Gemcitabine with or without VX - 970 in Metastatic Urothelial Carcinoma
A Phase III, Multicenter, Randomized, Placebo - Controlled Study of Atezolizumab (ANTI − PD - L1 Antibody) as Monotherapy and in Combination with Platinum - Based Chemotherapy in Patients with Untreated Locally Advanced or Metastatic Urothelial Carcinoma
In recent years, a number of new agents have been approved for treatment of urothelial carcinoma.
• Documented FGF / FGFR alteration and have either 1a) failed at least 1 previous treatment for their metastatic or surgically unresectable urothelial carcinoma (ie, chemotherapy, immunotherapy) or 1b) have not received chemotherapy due to poor ECOG status or 2) have insufficient renal function.
Molecular characterization data from The Cancer Genome Atlas and other groups demonstrate that almost all urothelial carcinomas of the bladder harbor a chromatin modifier gene mutation.
No expansion cohort in pancreatic cancer is being conducted, but phase II expansions are now ongoing in patients with NSCLC, SCCHN, urothelial carcinoma, melanoma, gastric or gastroesophageal junction cancer, and triple - negative breast cancer.
Urothelial Carcinoma is also an outcome of chronic urinary tract inflammatory condition.
Urothelial carcinoma (also called transitional cell carcinoma (TCC)-RRB- is the most commonly diagnosed cancer of the urinary tract of dogs.